newsfilter
← Latest News
Business Wire·

Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024

Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 ("NPC1") to be highlighted in a platform presentation Cyclo Therapeutics, Inc. (NASDAQ:CYTH)